Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
about
Hematologic toxicity in anal cancer patients during combined chemo-radiation: a radiation oncologist perspective.Whole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery.Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.A prospective phase II study of magnetic resonance imaging guided hematopoietical bone marrow-sparing intensity-modulated radiotherapy with concurrent chemotherapy for rectal cancer.Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer.Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patientsDosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.A Phase II prospective nonrandomized trial of magnetic resonance imaging-guided hematopoietic bone marrow-sparing radiotherapy for gastric cancer patients with concurrent chemotherapy.Impact of bone marrow radiation dose on acute hematologic toxicity in cervical cancer: principal component analysis on high dimensional dataTechnical aspects of radiation therapy for anal cancer.A dosimetric analysis of volumetric-modulated arc radiotherapy with jaw width restriction vs 7 field intensity-modulated radiotherapy for definitive treatment of cervical cancer.Tomotherapy as an adjuvant treatment for gastroesophageal junction and stomach cancer may reduce bowel and bone marrow toxicity compared to intensity-modulated radiotherapy and volumetric-modulated arc therapy.Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.Fat composition changes in bone marrow during chemotherapy and radiation therapy.Spatial mapping of functional pelvic bone marrow using FLT PET.Plan comparison of volumetric-modulated arc therapy (RapidArc) and conventional intensity-modulated radiation therapy (IMRT) in anal canal cancer.IMRT, RapidArc® and conformal radiotherapy in the treatment of tumours of the anal canal.The influence of therapeutic radiation on the patterns of bone marrow in ovary-intact and ovariectomized miceAssociation between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapRTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canalComparison of four 3D conformal treatment techniques to optimise radiotherapy treatment for anal cancer3'-deoxy-3'-[¹⁸F]fluorothymidine PET quantification of bone marrow response to radiation dose.Bone marrow sparing in intensity modulated proton therapy for cervical cancer: Efficacy and robustness under range and setup uncertainties.IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer CenterHematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.Modeling early haematologic adverse events in conformal and intensity-modulated pelvic radiotherapy in anal cancer.[(18)F]Fluoro-2-deoxy-2-d-glucose versus 3'-deoxy-3'-[(18)F]fluorothymidine for defining hematopoietically active pelvic bone marrow in gynecologic patients.Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer.Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma.Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy.Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C.Sex-specific aspects of tumor therapy.The evolution of rectal and urinary toxicity and immune response in prostate cancer patients treated with two three-dimensional conformal radiotherapy techniques.The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis.Advances in the Management of Anal Cancer.Pencil-beam scanning proton therapy for anal cancer: a dosimetric comparison with intensity-modulated radiotherapy.Radiotherapy dose escalation with concurrent chemotherapy in locally advanced cervix cancer is feasible.Dosimetric predictors of acute haematological toxicity in oesophageal cancer patients treated with neoadjuvant chemoradiotherapyIncorporating 18FDG-PET-defined pelvic active bone marrow in the automatic treatment planning process of anal cancer patients undergoing chemo-radiation.Effect of oral supplementation with immunonutrients on radiation-induced hematologic toxicity in cancer patients.
P2860
Q30235359-2F6EC9FE-B593-4570-A507-42CCDE924AB9Q33398380-07EAD20D-4FA6-4A83-8BF4-E7AA7D2F3281Q33422634-CBADBE38-F34C-4B43-AC9F-A48B612F58FCQ33427911-94FA6CE8-2AB5-4255-8211-19E9086581D6Q33428648-0C03A46C-BA88-43DE-BF95-C501A3DA91EBQ33429717-B4CBA914-B4E0-4383-84A4-E363CD03061EQ33431168-4131122E-66C8-4EAB-8028-E6611A82FEA8Q33432469-575D24A0-1467-4835-96CA-4BECA5867F13Q33578833-AD0B2B43-065E-4ABB-9079-A2E51C70F92EQ33820797-06C0049B-7C05-4B93-84B8-042272BFB18DQ33823328-7648BE84-0313-4830-9711-A78D27AFD638Q33889360-C138E9A3-6B87-49BE-B3C3-011AE7FEB617Q34009168-A16B8BA0-81F3-4538-B16F-401586B45A2EQ34156572-85B2D34F-4485-4AA1-8D74-C81E2ECE3905Q34169627-4C2315F2-DEA3-4B24-B95E-C36E24FB5452Q34246244-6F0AF15B-C641-485E-82C7-1D0D73673C55Q34372829-47AEF750-A02B-4D2F-8D90-2E6D7F1A3E91Q34374553-C53E1731-3E01-4A53-B2AF-B04EB4A25BAFQ34434263-BB2F6C9E-E74D-4568-AFB3-AAAF7881D22AQ34478729-2FA284C3-5DB4-4F83-9E2B-7A5E78BA2D2FQ34803620-49B2AFB9-7162-482B-9806-73DC7B6AD54BQ35118693-8FC4136E-884A-4A5D-9134-21BDFA855C93Q35868207-C07B9A4C-B652-4460-B555-A5D73FF5C38AQ35927962-2AD9F73B-7E5C-4CAF-928B-3BD4D57478ADQ36067677-1AC91EF5-5C6B-4AEE-92BD-EA8049531870Q36369579-A5661DEC-D130-4065-96C6-E1204C4AD09DQ36609751-CEDD74F6-A944-48E4-B2EC-F8DE8FC36579Q36627147-FBDDC8EE-D076-4652-A9FD-A8C809160D3DQ36770084-D59F2251-0640-4ADF-8B37-8604CC212BAFQ36770157-9F052960-8FF9-4A0A-A17D-976E29CD36A4Q37264971-46510096-B7BF-4B4E-976F-6159C6218AC4Q37401172-6AAE7BD3-317E-4489-B4EB-55BEA8157D10Q38266168-FFE2D869-E653-41BB-ABC3-DCCD332CC0A4Q38344332-2DB4D6CC-92B9-4A3A-9764-2241354E8FD6Q38746232-6E3ED939-D99E-4873-9265-431D13EB4680Q41312134-51844A9C-4C2D-4B74-9440-A5340B83EB6DQ41599857-E49F21C4-29E6-44FD-9306-3A07FB404B0EQ41635449-D9070191-1F87-4C0D-86C7-A8AFAD51E7B4Q44682134-0BDC99C5-1F13-4C7C-9E50-B9D1F397C462Q46084020-83461232-932F-403B-AFED-E3B64610F874
P2860
Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Association between bone marro ...... ensity-modulated radiotherapy.
@ast
Association between bone marro ...... ensity-modulated radiotherapy.
@en
type
label
Association between bone marro ...... ensity-modulated radiotherapy.
@ast
Association between bone marro ...... ensity-modulated radiotherapy.
@en
prefLabel
Association between bone marro ...... ensity-modulated radiotherapy.
@ast
Association between bone marro ...... ensity-modulated radiotherapy.
@en
P2093
P50
P921
P1476
Association between bone marro ...... tensity-modulated radiotherapy
@en
P2093
Arno J Mundt
Ashesh B Jani
Bulent Aydogan
David A Schomas
Hedy L Kindler
Joseph K Salama
Kiran Devisetty
Steven J Chmura
P304
P356
10.1016/J.IJROBP.2007.08.074
P407
P577
2007-11-08T00:00:00Z